published meta-analysis   sensitivity analysis   studies

control in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsThomas (vitamin c only), 2021 2.11 [0.07; 64.28] 2.11[0.07; 64.28]Thomas (vitamin c only), 202110%98NAnot evaluable clinical improvementdetailed resultsThomas (vitamin c only), 2021 3.14 [0.60; 16.38] 3.14[0.60; 16.38]Thomas (vitamin c only), 202110%98NAnot evaluable clinical improvement (7-day)detailed resultsThomas (vitamin c only), 2021 3.14 [0.60; 16.38] 3.14[0.60; 16.38]Thomas (vitamin c only), 202110%98NAnot evaluable hospitalizationdetailed resultsThomas (vitamin c only), 2021 0.68 [0.11; 4.27] 0.68[0.11; 4.27]Thomas (vitamin c only), 202110%98NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-05-23 12:35 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 649,650,589,651,968 - roots T: 290